{"protocolSection":{"identificationModule":{"nctId":"NCT03480698","orgStudyIdInfo":{"id":"EVER-AT0717"},"organization":{"fullName":"Ever Neuro Pharma GmbH","class":"INDUSTRY"},"briefTitle":"Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness","officialTitle":"C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke","acronym":"C-REGS2"},"statusModule":{"statusVerifiedDate":"2023-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-04-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-04-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-09-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2018-03-22","studyFirstSubmitQcDate":"2018-03-28","studyFirstPostDateStruct":{"date":"2018-03-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-12-11","lastUpdatePostDateStruct":{"date":"2023-12-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ever Neuro Pharma GmbH","class":"INDUSTRY"},"collaborators":[{"name":"IDV Data analysis and study planning Dr. Rahlfs","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.","detailedDescription":"Patients registered: Acute Ischemic Stroke patients with moderate to severe neurological deficits\n\nAll patients receive acute stroke care according to local treatment standards, not amended or influenced by the study:\n\nCerebrolysin Group:\n\nPatients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with terms of the local marketing authorization\n\nControl group:\n\nPatients who are not treated with Cerebrolysin\n\nObservation criteria:\n\n* Signed Informed Consent\n* Clinical diagnosis of acute ischemic stroke confirmed by imaging\n* Moderate to severe neurological deficits with NIH Stroke Scale (NIHSS) 8 to 15, both inclusive\n* No prior stroke\n* No prior disability\n* Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)\n* Reasonable expectation of successful follow-up (max. 100 days)\n\nThe study follows the recommendations of the Principles for Good Research on Comparative Effectiveness (GRACE).\n\nIn order to comply with recent calls for high-quality non-interventional comparative effectiveness research, a risk-based centralized statistical approach to monitoring is introduced in combination with targeted on-site monitoring for ongoing surveillance of study conduct, thus ensuring highest standards of data quality and integrity according to the most recent requirements of the ICH E6 Guideline for Good Clinical Practice (GCP, Amendment R2, July 2015), the FDA Guidance for Industry on a Risk-based Approach to Monitoring, and the EMA reflection-paper on risk-based quality management in clinical trials."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["acute ischemic stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"90 Days","designInfo":{"observationalModel":"OTHER","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":2000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cerebrolysin and standard stroke care","interventionNames":["Drug: Cerebrolysin"]},{"label":"Standard stroke care"}],"interventions":[{"type":"DRUG","name":"Cerebrolysin","description":"Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.","armGroupLabels":["Cerebrolysin and standard stroke care"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Ordinal modified Rankin Scale (mRS) at 3 months after stroke onset","description":"The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.","timeFrame":"3 months"}],"secondaryOutcomes":[{"measure":"Ordinal NIH Stroke Scale (NIHSS) at 21 days and 3 months after stroke onset","description":"The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.","timeFrame":"Day 21 and 3 months"},{"measure":"Ordinal modified Rankin Scale (mRS) at 21 days after stroke onset","description":"The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.","timeFrame":"21 days"},{"measure":"Proportion of patients with excellent recovery (mRS score 0-1) at 3 months after stroke onset","description":"The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.","timeFrame":"3 months"},{"measure":"Proportion of patients with functional independence (mRS score 0-2) at 3 months after stroke onset","description":"The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.","timeFrame":"3 months"},{"measure":"Ordinal MoCA at 3 months after stroke","description":"The Montreal Cognitive Assessment (MoCA) is a widely used screening assessment for detecting cognitive impairment. The MoCA test is a one-page 30-point test administered in approximately 10 minutes. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.","timeFrame":"3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed Informed Consent\n* Clinical diagnosis of acute ischemic stroke confirmed by imaging\n* Moderate to severe neurological deficits with NIH Stroke Scale (NIHSS) 8 to 15, both inclusive\n* No prior stroke\n* No prior disability\n* Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)\n* Reasonable expectation of successful follow-up (max. 100 days)\n\nExclusion Criteria:\n\n* none","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with moderate to severe neurological deficits after acute ischemic stroke (NIHSS 8-15) at baseline","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Marion Jech, Dr","role":"CONTACT","phone":"+43 7665 20555","phoneExt":"416","email":"marion.jech@everpharma.com"},{"name":"Stefan Winter, Dr","role":"CONTACT","phone":"+43 7665 20555","phoneExt":"422","email":"stefan.winter@everpharma.com"}],"overallOfficials":[{"name":"Michael Brainin, Univ.-Prof. Dr.","affiliation":"Danube University Krems - Head of the Department for Clinical Neuroscience and Preventive Medicine / Head of the Center for Neurosciences","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Landesklinikum Amstetten","status":"RECRUITING","city":"Amstetten","zip":"3300","country":"Austria","contacts":[{"name":"Susanne Asenbaum-Nan, MD, MBA, MSc","role":"CONTACT"}],"geoPoint":{"lat":48.1229,"lon":14.87206}},{"facility":"Krankenhaus der Barmherzigen Brüder Eisenstadt","status":"RECRUITING","city":"Eisenstadt","zip":"7000","country":"Austria","contacts":[{"name":"Dimitre Staykov, MD","role":"CONTACT"}],"geoPoint":{"lat":47.84565,"lon":16.52327}},{"facility":"Universitätsklinik Innsbruck","status":"RECRUITING","city":"Innsbruck","zip":"6020","country":"Austria","contacts":[{"name":"Stefan Kiechl, Prof. Dr.","role":"CONTACT"}],"geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Kepler Universitätsklinikum","status":"RECRUITING","city":"Linz","zip":"4021","country":"Austria","contacts":[{"name":"Milan Vosko, Dr., PhD","role":"CONTACT"}],"geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"CDK Salzburg, Universitätsklinik für Neurologie","status":"RECRUITING","city":"Salzburg","zip":"5020","country":"Austria","contacts":[{"name":"Johannes Mutzenbach, Dr.","role":"CONTACT"}],"geoPoint":{"lat":47.79941,"lon":13.04399}},{"facility":"UK St. Pölten","status":"RECRUITING","city":"St. Pölten","zip":"3100","country":"Austria","contacts":[{"name":"Stefan Oberndorfer, MD","role":"CONTACT"}],"geoPoint":{"lat":48.2,"lon":15.63333}},{"facility":"UK Tulln","status":"RECRUITING","city":"Tulln","zip":"3430","country":"Austria","contacts":[{"name":"Cornelia Brunner, MD","role":"CONTACT"}],"geoPoint":{"lat":48.32829,"lon":16.05858}},{"facility":"LK Wiener Neustadt","status":"RECRUITING","city":"Wiener Neustadt","zip":"2700","country":"Austria","contacts":[{"name":"Peter Schnider, MD","role":"CONTACT"}],"geoPoint":{"lat":47.80484,"lon":16.23201}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000006952","term":"Cerebrolysin"}],"ancestors":[{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018697","term":"Nootropic Agents"}],"browseLeaves":[{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M351658","name":"Cerebrolysin","asFound":"VII","relevance":"HIGH"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"NootAg","name":"Nootropic Agents"}]}},"hasResults":false}